ABBOTT LABORATORIES (ABT) — SEC Filings

Latest SEC filings for ABBOTT LABORATORIES (ABT), explained in plain English.

Sentiment Overview: 2 bullish, 28 neutral

Recent Filings (30)

• Abbott Labs Files S-8 for Employee Stock Plans — S-8 · 2026-03-23T17:30:42-04:00 [neutral]
  Abbott Laboratories filed an S-8 on March 23, 2026, to register securities for its employee benefit plans. This filing, with SEC Accession No. 0001104659-26-033
• Abbott Labs Files 8-K on Officer Changes & Filings — 8-K · 2025-12-12T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed an 8-K on December 12, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment o
• 8-K Filing — 8-K · 2025-11-21T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-11-20T00:00:00.000Z [neutral]
• Abbott's Q3 Net Earnings Flat Amid Strong Device Sales, COVID Test Slump — 10-Q · 2025-10-29T00:00:00.000Z [bullish] Risk: medium
  Abbott Laboratories reported a slight decrease in net earnings for the three months ended September 30, 2025, at $1,644 million, compared to $1,646 million in t
• Abbott Labs Files 8-K on Financials — 8-K · 2025-10-15T00:00:00.000Z [neutral] Risk: low
  On October 15, 2025, Abbott Laboratories filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well
• Abbott Posts Strong Q2 Growth, Net Sales Up 4.9% — 10-Q · 2025-07-30T00:00:00.000Z [bullish] Risk: low
  Abbott Laboratories reported robust financial performance for the second quarter ended June 30, 2025, with net sales reaching $10.465 billion, a significant inc
• Abbott Labs Files 8-K on Operations and Financials — 8-K · 2025-07-17T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed an 8-K on July 17, 2025, reporting on its results of operations and financial condition, and filing financial statements and exhibits.
• Abbott Labs Reports Director and Officer Changes — 8-K · 2025-05-01T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed an 8-K on May 1, 2025, reporting changes effective April 25, 2025. The filing pertains to the departure of directors, election of dire
• Abbott Labs Files Q1 2025 10-Q — 10-Q · 2025-04-30T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial performance and position, including its fisc
• Abbott Labs Files 8-K on Security Holder Vote Matters — 8-K · 2025-04-28T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed an 8-K report on April 28, 2025, indicating a submission of matters to a vote of security holders. The report pertains to events occur
• Abbott Labs Files 8-K on Financials — 8-K · 2025-04-16T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed an 8-K on April 16, 2025, reporting on its results of operations and financial condition, and providing financial statements and exhib
• DEF 14A Filing — DEF 14A · 2025-03-14T00:00:00.000Z [neutral]
• Abbott Labs Files 2024 10-K — 10-K · 2025-02-21T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed its 2024 10-K on February 21, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered at 100 Abbott Pa
• Abbott Labs Files 8-K on Financials — 8-K · 2025-01-22T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed an 8-K on January 22, 2025, reporting on its results of operations and financial condition. The filing includes financial statements a
• Abbott Labs Announces Executive and Director Changes — 8-K · 2024-11-15T00:00:00.000Z [neutral] Risk: medium
  Abbott Laboratories announced on November 12, 2024, changes in its executive team. Specifically, the company reported the departure of certain officers and the
• Abbott Labs Files Q3 2024 10-Q — 10-Q · 2024-10-31T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quar
• Abbott Labs Files 8-K on Operations and Financials — 8-K · 2024-10-16T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed an 8-K on October 16, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibi
• Abbott Labs Files Q2 2024 10-Q — 10-Q · 2024-07-31T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed its 10-Q for the period ending June 30, 2024. The filing covers the second quarter and first half of 2024, detailing financial perform
• Abbott Labs Files 8-K on Operations and Financials — 8-K · 2024-07-18T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed an 8-K on July 18, 2024, to report on its results of operations and financial condition, as well as to file financial statements and e
• Abbott Labs Files Q1 2024 10-Q — 10-Q · 2024-05-02T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed its 10-Q for the period ending March 31, 2024. The company reported financial results for the first quarter of 2024, detailing its rev
• Abbott Labs Reports Officer and Director Changes — 8-K · 2024-05-01T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed an 8-K on May 1, 2024, reporting changes effective April 26, 2024. The filing pertains to the departure of directors or certain office
• Abbott Labs Files 8-K on Shareholder Votes — 8-K · 2024-04-29T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories (ABT) filed an 8-K on April 29, 2024, reporting on matters submitted to a vote of security holders as of April 26, 2024. The filing details
• Abbott Labs Files 8-K on Q1 Financials — 8-K · 2024-04-17T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed an 8-K on April 17, 2024, reporting on its results of operations and financial condition. The filing covers the period from January 1,
• Abbott Labs Files 2024 Proxy Statement — DEF 14A · 2024-03-15T00:00:00.000Z [neutral] Risk: low
  Abbott Laboratories filed its DEF 14A proxy statement on March 15, 2024, for the fiscal year ending December 31, 2023. The filing details executive compensation
• Abbott Labs Files 2023 10-K, Details Fiscal Year Performance — 10-K · 2024-02-16T00:00:00.000Z [neutral] Risk: medium
  Abbott Laboratories filed its 10-K on February 16, 2024, for the fiscal year ending December 31, 2023. The company, a pharmaceutical preparations firm (SIC 2834
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• Abbott Labs Reports Material Agreements & New Financial Obligation — 8-K · 2024-01-29T00:00:00.000Z [neutral]
  Abbott Laboratories filed an 8-K on January 29, 2024, indicating an "Entry into a Material Definitive Agreement," "Termination of a Material Definitive Agreemen
• BlackRock Amends Abbott Labs Stake, Signals Continued Confidence — SC 13G/A · 2024-01-26T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating its ownership of Abbott Laboratories' Common Stock as of December 31, 2023. This is Ame
• Abbott Labs Files 8-K on Financial Results & Operations — 8-K · 2024-01-24T00:00:00.000Z [neutral]
  Abbott Laboratories filed an 8-K on January 24, 2024, to report its results of operations and financial condition, as well as related financial statements and e